Skip to main content
    A

    Aurinia Pharmaceuticals Inc (AUPH)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $15.48
    -0.25 (-1.59%)

    Market Cap: $2.11B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Aurinia Pharmaceuticals Inc (AUPH) Financials: Revenue, Profit and Cash Flow

    Updated Oct 30, 2026. Financial statements from company filings, amounts in US dollars.

    Aurinia Pharmaceuticals reported revenue of $283.06M for the fiscal year ended Dec 31, 2025, up 20.4% from the year before. That year, net income was $287.20M with a net margin of 101.5%, operating cash flow was $135.66M and free cash flow was $135.41M. The quarter ended Sep 30, 2026 had revenue of $83.70M and net income of $31.70M.

    Revenue and Margins

    The operating margin was 37.1% in the fiscal year ended Dec 2025, the highest of the 4 years shown with an operating margin. Over the 9 years to Dec 2025, revenue grew from $173.00K, a compound annual rate of 127.6%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$283.06M+20.4%88.5%37.1%101.5%
    Dec 2024$235.13M+34.0%88.0%-2.0%2.4%
    Dec 2023$175.51M+31.0%91.9%-52.2%-44.5%
    Dec 2022$134.03M+193.9%95.8%-83.2%-80.7%
    Dec 2021$45.60M-9.0%97.6%-396.3%-396.8%
    Dec 2020$50.12M+15660.4%100.0%-208.1%-204.9%
    Dec 2019$318.00K-31.3%100.0%-28598.4%-27794.0%
    Dec 2018$463.00K+10.8%100.0%-11930.9%-11464.1%
    Dec 2017$418.00K+141.6%100.0%-11212.4%-16935.9%
    Dec 2016$173.00KN/A0.6%-14466.5%-13465.3%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 4894.8% from the year before. In the quarter ended Sep 2026, net income rose 0.5% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$283.06M$235.13M$175.51M$134.03M$45.60M$50.12M$318.00K$463.00K$418.00K$173.00K
    Cost of revenue$32.66M$28.25M$14.15M$5.66M$1.09M$0$0$0$0$4.00K
    Gross profit$250.39M$206.88M$161.37M$128.37M$44.51M$50.12M$318.00K$463.00K$418.00K$1.00K
    Research and development$32.51M$20.79M$49.64M$44.99M$51.14M$50.33M$52.87M$41.38M$33.93M$14.53M
    Operating income$104.91M-$4.69M-$91.69M-$111.47M-$180.74M-$104.29M-$90.94M-$55.24M-$46.87M-$25.03M
    Net income$287.20M$5.75M-$78.02M-$108.18M-$180.97M-$102.68M-$88.39M-$53.08M-$70.79M-$23.30M
    EBITDA$114.18M$2.03MN/A-$110.34M-$177.31M-$102.92M-$89.77M-$53.93MN/A-$22.01M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$83.70M$83.22M$77.70M$77.11M$73.47M$70.01M$62.47M$59.87M$67.77M$57.19M$50.30M$45.09M
    Gross profit$75.39M$76.67M$71.20M$68.31M$65.29M$62.89M$53.89M$54.31M$61.74M$48.28M$42.55M$39.70M
    Operating income$35.36M$46.34M$41.42M$33.24M$29.75M$20.08M$21.85M-$1.67M$11.75M-$1.51M-$13.25M-$29.67M
    Net income$31.70M$37.41M$34.35M$210.79M$31.55M$21.51M$23.34M$1.43M$14.35M$722.00K-$10.75M-$26.88M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $17.59M by $62.62M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$751.59M$550.64M$548.06M$470.86M$543.37M$463.66M$324.30M$145.86M$189.85M$57.00M
    Current assets$491.97M$446.60M$424.80M$442.54M$513.32M$419.43M$315.14M$132.85M$175.25M$39.73M
    Cash and equivalents$80.21M$83.43M$48.88M$94.17M$231.90M$272.35M$306.02M$117.97M$165.63M$39.65M
    Total liabilities$170.26M$173.17M$170.11M$65.42M$64.28M$55.91M$25.70M$33.29M$24.10M$21.05M
    Short-term debt$17.59M$15.07M$15.60M$936.00K$1.06M$788.00K$6.91M$118.00K$4.07M$2.93M
    Long-term debtN/AN/AN/AN/AN/AN/AN/A$21.75M$11.79M$9.14M
    Shareholder equity$581.33M$377.48M$377.95M$405.44M$479.09M$407.75M$298.60M$112.58M$165.74M$971.00K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$825.70M$792.26M$724.00M$751.59M$527.53M$502.56M$504.85M$550.64M$549.36M$523.53M$516.63M$548.06M
    Total liabilities$168.19M$177.40M$156.37M$170.26M$161.76M$167.26M$154.66M$173.17M$161.36M$158.91M$157.16M$170.11M
    Cash and equivalents$46.15M$179.83M$41.01M$80.21M$73.19M$53.00M$66.43M$83.43M$37.14M$33.41M$64.46M$48.88M
    Shareholder equity$657.52M$614.86M$567.63M$581.33M$365.77M$335.30M$350.19M$377.48M$388.00M$364.62M$359.48M$377.95M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 99.8% of operating cash flow. Share repurchases came to 72.5% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$135.66M$44.39M-$33.46M-$79.53M-$157.69M-$69.86M-$63.59M-$51.61M-$41.17M-$20.76M
    Capital expenditures$252.00K$281.00K$718.00K$292.00K$1.50M$7.34M$85.00K$74.00K$25.00K$25.00K
    Free cash flow$135.41M$44.11M-$34.18M-$79.82M-$159.19M-$77.20M-$63.67M-$51.69M-$41.19M-$20.78M
    Share repurchases$98.16M$40.24M$0$0N/AN/AN/AN/AN/AN/A
    Investing cash flow-$32.77M$39.26M-$6.71M-$60.63M-$103.87M-$158.19M$7.78M-$65.00K-$8.00M$31.15M
    Financing cash flow-$106.11M-$49.09M-$5.13M$2.43M$221.11M$194.38M$243.85M$4.01M$175.15M$33.96M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$46.37M$52.57M$32.56M$45.67M$44.45M$44.24M$1.30M$30.11M$17.03M$15.84M-$18.60M$14.31M
    Capital expenditures$24.00KN/A$39.00K$72.00K$65.00K$98.00K$17.00K$56.00K$85.00K$128.00K$12.00K$299.00K
    Free cash flow$46.34MN/A$32.52M$45.60M$44.38M$44.14M$1.28M$30.06M$16.94M$15.71M-$18.61M$14.01M
    Last 12 quarters

    Frequently Asked Questions About AUPH

    What is Aurinia Pharmaceuticals' annual revenue?

    Aurinia Pharmaceuticals reported revenue of $283.06M for the fiscal year ended Dec 31, 2025.

    How fast is Aurinia Pharmaceuticals' revenue growing?

    Revenue was up 20.4% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 28.3%.

    Is Aurinia Pharmaceuticals profitable?

    Yes. Aurinia Pharmaceuticals reported net income of $287.20M for the fiscal year ended Dec 31, 2025, with a net margin of 101.5%.

    How much free cash flow does AUPH generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $135.66M minus capital expenditures of $252.00K produced free cash flow of $135.41M.

    How much debt does Aurinia Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $17.59M and cash and equivalents of $80.21M.